Answers are grounded in this paper and cite their sources.
Background and Aims Metastatic pancreatic ductal adenocarcinoma (mPDAC) has a 5-year survival rate of 3%. In nonmetastatic, locally advanced pancreatic cancer, the addition to chemotherapy of EUS-guided intratumoral phosphorus-32 ( 32 P) microparticle implantation has achieved good local disease control. The aim of this study was to report the clinical outcomes of this treatment in patients with mPDAC. Methods Patients with mPDAC treated with chemotherapy and intratumoral 32 P-microparticles from 5 centers in Australia and the United Kingdom were analyzed retrospectively. Results Fourteen patients were treated (7 female subjects; median age, 64.5 years; Eastern Cooperative Oncology Group performance status scores 0/1/2, 21.4%/57.1%/21.4%). The median baseline primary tumor longest diameter was 40.5 mm. Patients had a median of 3 metastases (interquartile range, 2.25 to 5) and received either 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (n = 4) or gemcitabine/nab-paclitaxel (n = 10). 32 P microparticles were implanted at a median 3.1 months from chemotherapy commencement. Local disease control rate at 3 months' postimplantation was 100%. Primary tumor longest diameter decreased by 25% (interquartile range, –31.4% to –16.7%; P = .008), and serum cancer antigen 19-9 levels declined from 134 U/mL to 66 U/mL ( P = .018). Local progression-free survival was 12.2 months (95% CI, 9.0-15.4 months) from chemotherapy commencement and 8.3 months (95% CI, 2.6-16.0 months) from 32 P microparticle implantation. Therapy was associated with improved quality of life, including global health status at 12 weeks' postimplantation ( P = .037). Median overall survival was 13.8 months (95% CI, 10.5-17.1 months) from chemotherapy commencement and 11 months (95% CI, 5.6-17.4 months) from 32 P microparticle implantation. No grade 4/5 acute toxicities were observed. Conclusions This first multicenter analysis of combined chemotherapy and EUS-guided 32 P microparticle implantation in mPDAC shows the potential clinical benefits of local tumor control in a cohort for whom outcomes are historically poor.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: